Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis

BACKGROUND: One year of adjuvant trastuzumab in combination with chemotherapy is the standard of care in early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Existing data on shortening trastuzumab treatment show conflicting results. METHODS: A search of PubMed and abs...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:JNCI Cancer Spectr
Prif Awduron: Goldvaser, Hadar, Korzets, Yasmin, Shepshelovich, Daniel, Yerushalmi, Rinat, Sarfaty, Michal, Ribnikar, Domen, Thavendiranathan, Paaladinesh, Amir, Eitan
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2019
Pynciau:
Meta-Analysis
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6649709/
https://ncbi.nlm.nih.gov/pubmed/31360906
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jncics/pkz033
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg